Equities research analysts forecast that Iqvia Holdings Inc (NYSE:IQV) will post $2.44 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Iqvia’s earnings. The highest sales estimate is $2.45 billion and the lowest is $2.43 billion. Iqvia posted sales of $1.91 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 27.7%. The company is scheduled to issue its next quarterly earnings results on Wednesday, May 2nd.
On average, analysts expect that Iqvia will report full-year sales of $2.44 billion for the current year, with estimates ranging from $10.11 billion to $10.16 billion. For the next year, analysts expect that the company will post sales of $10.48 billion per share, with estimates ranging from $9.00 billion to $10.82 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Iqvia.
Iqvia (NYSE:IQV) last issued its earnings results on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.34 by ($0.02). The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. Iqvia’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.09 EPS.
In other Iqvia news, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total transaction of $764,776,314.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $101.21, for a total transaction of $1,012,100.00. The disclosure for this sale can be found here. Insiders have sold 8,727,078 shares of company stock valued at $890,124,079 over the last three months. 6.40% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Winslow Evans & Crocker Inc. bought a new position in shares of Iqvia during the fourth quarter worth $123,000. Focused Wealth Management Inc bought a new position in shares of Iqvia during the fourth quarter worth $166,000. Valeo Financial Advisors LLC bought a new position in shares of Iqvia during the fourth quarter worth $170,000. IFP Advisors Inc bought a new position in shares of Iqvia during the fourth quarter worth $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Iqvia during the fourth quarter worth $209,000. 96.09% of the stock is owned by hedge funds and other institutional investors.
Shares of Iqvia (IQV) traded down $0.40 during trading hours on Friday, reaching $99.57. 1,146,404 shares of the company were exchanged, compared to its average volume of 1,234,110. Iqvia has a one year low of $76.51 and a one year high of $110.67. The stock has a market cap of $20,790.00, a PE ratio of 66.38, a PEG ratio of 1.82 and a beta of 0.61. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.19 and a current ratio of 1.19.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.